Shanghai Bio-heart Biological Technology Co., Ltd. announced at the AGM held on June 27, 2022 that the company approved reappointment of Ernst & Young as auditor for a term until the conclusion of the next annual general meeting of the Company.
Shanghai Bio-heart Biological Technology Co., Ltd.
Equities
2185
CNE100004JH3
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.1 HKD | +1.94% | +3.96% | -38.60% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-38.60% | 65.44M | |
+9.68% | 125B | |
-7.58% | 10.91B | |
+2.17% | 8.93B | |
+22.75% | 7.57B | |
+33.99% | 5.36B | |
+8.12% | 3.43B | |
-8.48% | 2.81B | |
-5.07% | 2.23B | |
-4.22% | 2.13B |
- Stock Market
- Equities
- 2185 Stock
- News Shanghai Bio-heart Biological Technology Co., Ltd.
- Shanghai Bio-Heart Biological Technology Co., Ltd. Approves Reappointment of Ernst & Young as Auditor